Otezla
Q2 2026 sales fell 21% to $491 million.
The numbers
Otezla product sales$491 millionQ2 2026 · down 21% year over year · source ↗
What it is
Oral medicine for plaque psoriasis and psoriatic arthritis. Its sales are shrinking as competition increases in the market.
Why it matters to the stock. Otezla is a sizeable cash product with a declining trend that affects Amgen's near-term revenue guidance.
News
No stories tagged to this project yet.